Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2.

Management strategies for metastatic castration-resistant prostate cancer (mCRPC) have rapidly shifted in recent years. As novel imaging and therapeutic approaches have made their way to the clinic, providers are encountering increasingly challenging clinical scenarios, with limited guidance from the current literature.

The US Prostate Cancer Conference (USPCC) is a multidisciplinary meeting of prostate cancer experts intended to address the many challenges of prostate cancer management. At the first annual USPCC meeting, areas of controversy and consensus were identified during a 2-day meeting that included expert presentations, full-panel discussions, and postdiscussion responses to questions developed by the USPCC cochairs and session moderators.

This narrative review covers the USPCC expert discussion and perspectives relevant to mCRPC, including neuroendocrine/aggressive-variant prostate cancer (NEPC/AVPC). Areas of broad agreement identified among USPCC experts include the benefits of poly (ADP-ribose) polymerase (PARP) inhibitors for patients with BRCA1/2 mutations, the use of radioligand therapy in patients with prostate-specific membrane antigen (PSMA)-positive mCRPC, and the need for clinical trials that address real-world clinical questions, including the performance of novel therapies when compared with modern standard-of-care treatment. Ongoing areas of controversy and uncertainty included the appropriateness of PARP inhibitors in patients with non-BRCA1/2 mutations, the optimal definition of PSMA positivity, and systemic therapies for patients with NEPC/AVPC after progression on platinum-based therapies.

The first annual USPCC meeting identified several areas of controversy in the management of mCRPC, highlighting the urgent need for clinical trials designed to facilitate treatment selection and sequencing in this heterogeneous disease state.

JU open plus. 2024 Apr 15 [Epub]

Alan H Bryce, E David Crawford, Neeraj Agarwal, Maha H Hussain, Himisha Beltran, Matthew R Cooperberg, Daniel P Petrylak, Neal Shore, Daniel E Spratt, Scott T Tagawa, Emmanuel S Antonarakis, Ana M Aparicio, Andrew J Armstrong, Thomas P Boike, Jeremie Calais, Michael A Carducci, Brian F Chapin, Michael S Cookson, John W Davis, Tanya Dorff, Scott E Eggener, Felix Y Feng, Martin Gleave, Celestia Higano, Andrei Iagaru, Alicia K Morgans, Michael Morris, Katie S Murray, Wendy Poage, Matthew B Rettig, Oliver Sartor, Howard I Scher, Paul Sieber, Eric Small, Sandy Srinivas, Evan Y Yu, Tian Zhang, Phillip J Koo

Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona., Department of Urology, University of California San Diego, La Jolla, California., Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah., Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois., Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts., Department of Urology, University of California at San Francisco, San Francisco, California., Yale New Haven Health, New Haven, Connecticut., Carolina Urologic Research Center/Genesis Care, Myrtle Beach, South Carolina., University Hospitals Seidman Cancer Center, Cleveland, Ohio., Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, New York., Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota., Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina., Michigan Healthcare Professionals, Troy, Michigan., Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California., Hopkins Kimmel Cancer Center, Baltimore, Maryland., Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma., City of Hope Comprehensive Cancer Center, Duarte, California., Departments of Surgery (Urology), University of Chicago Medical Center, Chicago, Illinois., Departments of Radiation Oncology, Urology, and Medicine, University of California San Francisco, San Francisco, California., Urological Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada., University of British Columbia, Vancouver, British Columbia, Canada., Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California., Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Department of Urology, NYU Langone Health, New York, New York., Prostate Conditions Education Council, Centennial, Colorado., Department of Medicine, Division of Hematology-Oncology, VA Greater Los Angeles, Los Angeles, California., Tulane Cancer Center, New Orleans, Louisiana., Keystone Urology Specialists, Lancaster, Pennsylvania., UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California., Division of Medical Oncology, Stanford University Medical Center, Stanford, California., Department of Medicine, Division of Hematology & Oncology, University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington., Division of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas., Banner MD Anderson Cancer Center, Phoenix, Arizona.